

Clinical trials of ivabradine 20mg

TrialResults-center www.trialresultscenter.org

1 stable angina

| Trial | Treatments | Patients | Trials design and methods |
|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| ivabradine 20mg vs placebo | | | |
| SIGNIFY , 2014 [ISRCTN61576291] n=9550/9552 follow-up: 27.8 mo (median) | ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. versus placebo | patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more | Parallel groups double-blind |
| Borer (CL2-009) 20mg , 2003 n=88/91 follow-up: 2 weeks | ivabradine 10mg twice daily (20mg/d) versus placebo | | double blind |
| ivabradine 20mg vs amlodipine | | | |
| Ruzylo (CL3-023) 20mg , 2007 n=391/404 follow-up: 3 months | ivabradine 10mg twice daily versus amlodipine 10mg once daily | Patients with a \geq 3-month history of chronic, stable effort-induced angina | Parallel groups double-blind |
| ivabradine 20mg vs atenolol | | | |
| INITIATIVE (CL3-017, Tardif) 20mg , 2005 n=317/307 follow-up: 16 weeks | ivabradine 5 mg bid for 4 weeks and then 10 mg bid for 12 weeks versus atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks | patients with stable angina | Parallel groups double-blind |

More details and results :

- HR-slowing agents for stable angina in all type of patients at <http://www.trialresultscenter.org/go-Q262>

References

SIGNIFY, 2014:

Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. N Engl J Med 2014 Aug 31; [25176136] [10.1056/NEJMoa1406430](https://doi.org/10.1056/NEJMoa1406430)

Borer (CL2-009) 20mg, 2003:

Ruzylo (CL3-023) 20mg, 2007:

Ruzylo W, Tendera M, Ford I, Fox KM Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. *Drugs* 2007;67:393-405 [[17335297](#)]

INITIATIVE (CL3-017, Tardif) 20mg, 2005:

Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. *Eur Heart J* 2005 Dec;26:2529-36 [[16214830](#)]

Entry terms: ivabradine, ivabradine, Corlanor, Procorolan, S 16257-2, S-16257-2, S-16260-2, S 16260-2, S 16257, S-16257,